137 related articles for article (PubMed ID: 31330833)
1.
Marisi G; Petracci E; Raimondi F; Faloppi L; Foschi FG; Lauletta G; Iavarone M; Canale M; Valgiusti M; Neri LM; Ulivi P; Orsi G; Rovesti G; Vukotic R; Conti F; Cucchetti A; Ercolani G; Andrikou K; Cascinu S; Scartozzi M; Casadei-Gardini A
Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31330833
[TBL] [Abstract][Full Text] [Related]
2. Association of
Casadei-Gardini A; Marisi G; Dadduzio V; Gramantieri L; Faloppi L; Ulivi P; Foschi FG; Tamburini E; Vivaldi C; Rizzato MD; Ielasi L; Canale M; Conti F; Rudnas B; Fornaro L; Silvestris N; Silletta M; Cardellino GG; Lonardi S; Fornari F; Orsi G; Rovesti G; Zagonel V; Cascinu S; Scartozzi M
Clin Cancer Res; 2020 Sep; 26(17):4485-4493. PubMed ID: 32371540
[TBL] [Abstract][Full Text] [Related]
3. Influence of NOS3 rs2070744 genotypes on hepatocellular carcinoma patients treated with lenvatinib.
Azuma S; Uojima H; Chuma M; Shao X; Hidaka H; Nakazawa T; Kondo M; Numata K; Iwabuchi S; Kako M; Maeda S; Koizumi W; Atsuda K
Sci Rep; 2020 Oct; 10(1):17054. PubMed ID: 33051476
[TBL] [Abstract][Full Text] [Related]
4. eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
Casadei Gardini A; Marisi G; Faloppi L; Scarpi E; Foschi FG; Iavarone M; Lauletta G; Corbelli J; Valgiusti M; Facchetti F; Della Corte C; Neri LM; Tamberi S; Cascinu S; Scartozzi M; Amadori D; Nanni O; Tenti E; Ulivi P; Frassineti GL
Oncotarget; 2016 May; 7(19):27988-99. PubMed ID: 27058899
[TBL] [Abstract][Full Text] [Related]
5. Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol.
Gardini AC; Faloppi L; Aprile G; Brunetti O; Caparello C; Corbelli J; Chessa L; Bruno D; Ercolani G; Leonetti A; Stefano G; Farella N; Foschi FG; Lanzi A; Dadduzio V; Marisi G; Masi G; Negri FV; Pagan F; Santini D; Scarpi E; Silletta M; Silvestris N; Tamburini E; Tassinari D; Vivaldi C; Gentilucci UV; Zagonel V; Calvetti L; Cascinu S; Frassineti GL; Scartozzi M
Tumori; 2018 Dec; 104(6):476-479. PubMed ID: 29739298
[TBL] [Abstract][Full Text] [Related]
6. NOS3 Gene rs1799983 and rs2070744 Polymorphisms in Patients with Unstable Angina.
Pawlik A; Błaszczyk H; Rać M; Maciejewska-Skrendo A; Safranow K; Dziedziejko V
J Vasc Res; 2020; 57(3):136-142. PubMed ID: 32224624
[TBL] [Abstract][Full Text] [Related]
7. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Scartozzi M; Faloppi L; Svegliati Baroni G; Loretelli C; Piscaglia F; Iavarone M; Toniutto P; Fava G; De Minicis S; Mandolesi A; Bianconi M; Giampieri R; Granito A; Facchetti F; Bitetto D; Marinelli S; Venerandi L; Vavassori S; Gemini S; D'Errico A; Colombo M; Bolondi L; Bearzi I; Benedetti A; Cascinu S
Int J Cancer; 2014 Sep; 135(5):1247-56. PubMed ID: 24510746
[TBL] [Abstract][Full Text] [Related]
8. Analysis of prognostic germline polymorphisms in patients with advanced hepatocellular carcinoma.
Herman M; Lok BH; Gallinger S; Dawson L; Kim R; Cheng D; Paton T; Bucur R; Patel D; Fazelzad R; Hueniken K; Liu G
Transl Gastroenterol Hepatol; 2023; 8():32. PubMed ID: 38021355
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib.
Oh CR; Kong SY; Im HS; Kim HJ; Kim MK; Yoon KA; Cho EH; Jang JH; Lee J; Kang J; Park SR; Ryoo BY
BMC Cancer; 2019 Apr; 19(1):292. PubMed ID: 30935424
[TBL] [Abstract][Full Text] [Related]
10. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
[TBL] [Abstract][Full Text] [Related]
11. Increased cumulative doses and appearance of hand-foot skin reaction prolonged progression free survival in sorafenib-treated advanced hepatocellular carcinoma patients.
Chang WT; Lu SN; Rau KM; Huang CS; Lee KT
Kaohsiung J Med Sci; 2018 Jul; 34(7):391-399. PubMed ID: 30063012
[TBL] [Abstract][Full Text] [Related]
12. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
[TBL] [Abstract][Full Text] [Related]
13. Association of NOS3 gene polymorphisms with essential hypertension in Sudanese patients: a case control study.
Gamil S; Erdmann J; Abdalrahman IB; Mohamed AO
BMC Med Genet; 2017 Nov; 18(1):128. PubMed ID: 29132319
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
[TBL] [Abstract][Full Text] [Related]
15. Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials.
Chen BB; Lin ZZ; Shao YY; Hsu C; Hsu CH; Cheng AL; Liang PC; Shih TT
Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638446
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
[TBL] [Abstract][Full Text] [Related]
17. Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction.
Al-Rajabi R; Patel S; Ketchum NS; Jaime NA; Lu TW; Pollock BH; Mahalingam D
J Gastrointest Oncol; 2015 Jun; 6(3):259-67. PubMed ID: 26029452
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
[No Abstract] [Full Text] [Related]
19. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
[TBL] [Abstract][Full Text] [Related]
20. Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Escudier B; Rini BI; Motzer RJ; Tarazi J; Kim S; Huang X; Rosbrook B; English PA; Loomis AK; Williams JA
Clin Genitourin Cancer; 2015 Aug; 13(4):328-337.e3. PubMed ID: 25816720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]